Bayer
Life-extending cancer and heart therapies
Leverkusen, North Rhine-Westphalia, Germany
Bayer is a multinational pharmaceutical and life sciences company headquartered in Leverkusen, Germany, with operations in over 80 countries. It operates through three main business divisions: Pharmaceuticals, Crop Science, and Consumer Health. Bayer is investing significantly in digital transformation, including hundreds of AI-driven initiatives across drug discovery, clinical trials, and healthcare applications.
How We Help
Core Technology
Cell and gene therapy platforms, precision medicine, pharmacogenetics, biomarkers, chemoproteomics, PROTACs, RNA-targeting small molecules, artificial intelligence, machine learning, big data, diagnostic imaging, advanced biotechnology, digital agriculture platforms, integrated seed and chemical offerings.
Key Differentiators
deployed generative AI for drug discovery including hypothesis generation and regulatory documentation automation; implemented AI for clinical trial planning and analysis; launched heart risk assessment tool powered by Huma; partnered with Google Cloud to develop AI solutions for radiologists
Clinical Focus
Cardiovascular diseases, oncology, women's healthcare, hematology, ophthalmology, neurology & rare diseases, immunology, as well as consumer health areas like pain relief, allergy, cold and flu, digestive health, dermatology, and nutritional supplements.
Target Customers
Consumers, patients, farmers, healthcare professionals, pharmacies, hospitals.
Product Stage
Mature
Company Info
- Business Model
- B2B, B2C (multifaceted across pharmaceuticals, consumer health, and crop science)
- Founded
- 1863
- Total Funding
- 8,312,000,000
- Website
- www.bayer.com
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
FDA approvals: Kerendia (heart failure, CKD/T2D), Nubeqa (prostate cancer - 46% progression reduction), Hyrnuo (HER2+ lung cancer accelerated), Lynkuet (menopause), Gadoquatrane (MRI contrast Japan first approval). Phase III ARANOTE, FINEARTS-HF, FIDELIO-DKD completed.
MedStartr Index Score
?What do you think of Bayer?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.